(NASDAQ: RLAY) Relay Therapeutics's forecast annual revenue growth rate of 49.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Relay Therapeutics's revenue in 2025 is $8,356,000.On average, 13 Wall Street analysts forecast RLAY's revenue for 2025 to be $2,207,953,863, with the lowest RLAY revenue forecast at $1,307,890,717, and the highest RLAY revenue forecast at $6,988,358,563. On average, 10 Wall Street analysts forecast RLAY's revenue for 2026 to be $2,371,916,839, with the lowest RLAY revenue forecast at $0, and the highest RLAY revenue forecast at $7,315,937,871.
In 2027, RLAY is forecast to generate $5,486,173,452 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $19,531,699,566.